Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen Idec Inc (BIIB): Orbimed Advisors Top Stocks in Q2

Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission. For the second quarter of 2014, the hedge fund revealed 132 equity positions, worth $8.5 billion. Orbimed Advisors is a large health care fund investing in companies at various stages from venture capital to the public markets. The largest holdings of the fund are represented by Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Bristol-Myers Squibb Co (NYSE:BMY), and Biogen Idec Inc (NASDAQ:BIIB). In this article, we will discuss each of these three largest positions for the second quarter.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is on the top position, where Orbimed Advisors currently owns 1.49 million shares. In its 13F, the fund reported ownership of 1.66 million shares of the company, with a value of more than $390 million. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases. For the second quarter of 2014, the company reported a net income of $33.5 million for the second quarter of 2014, compared to a net loss of $13.5 million for the second quarter of 2013.

Other hedge fund holding stakes in the company include Viking Global, managed by Andreas Halvorsen, which owns 208,077 shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), and Sectoral Asset Management, led by Jerome Pfund and Michael Sjostrom, which holds 73,993 shares of the company.

In Bristol-Myers Squibb Co (NYSE:BMY), Orbimed Advisors revealed holding 7.19 million shares, worth nearly $349 million. The stake represents an increase from 5.97 million shares the fund reported previously. Having a market cap of $83.5 billion, Bristol-Myers Squibb Co (NYSE:BMY) is a New-York-headquarted global biopharmaceutical company.

Last month, Bristol-Myers Squibb Co (NYSE:BMY) released its financial results for the second quarter of 2014. The company reported non-GAAP net earnings attributable to the company of $798 million, or $0.48 per share, compared to $730 million, or $0.44 per share, for the same period a year ago.

Other significant shareholders of the company include Adage Capital Management, managed by Phill Gross and Robert Atchinson, which reported holding 4.95 million shares, and Donald Chiboucis’ Columbus Circle Investors, which owns 2.89 million shares.

Biogen Idec Inc (NASDAQ:BIIB) is represented as the third largest holding, in which Orbimed Advisors disclosed owning 1.08 million shares, slightly up from 1.06 million shares the fund held earlier. The value of the position amounts to around $342 million. Biogen Idec Inc (NASDAQ:BIIB) is an independent biotechnology company engaged in development of innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Its market cap is $81.2 billion. For full-year 2014, Biogen Idec Inc (NASDAQ:BIIB) updated its financial guidance. It expects revenue growth to be approximately between 38% to 41%, and GAAP diluted EPS is expected to be between $11.26 and $11.46.

Aside from Orbimed Advisors, Columbus Circle Investors owns 1.35 million shares, and Cliff Asness’ AQR Capital Management holds 791,724 shares of the company.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!